Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.
Website: oncocyte.com



Growth: Bad revenue growth rate 0.0%, there is acceleration compared to average historical growth rates -22.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -4 050.0%. On average the margin is decreasing steadily. Gross margin is normal, +39.3%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 83% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 11.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 63.3% higher than minimum and 64.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -196.6x by EV / Sales multiple

Key Financials (Download financials)

Ticker: OCX
Share price, USD:  (0.0%)3.2
year average price 3.13  


year start price 2.05 2025-02-06

min close price 1.97 2025-02-07

max close price 4.17 2025-03-10

current price 3.20 2026-02-05
Common stocks: 8 090 000

Dividend Yield:  0.0%
EV / Sales: 10.4x
Margin (EBITDA LTM / Revenue): -4 050.0%
Fundamental value created in LTM:
Market Cap ($m): 26
Net Debt ($m): -5
EV (Enterprise Value): 21
Price to Book: -2.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-12seekingalpha.com

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

2025-04-02prismmediawire.com

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

2025-04-02globenewswire.com

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

2025-02-11globenewswire.com

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2025-02-10prismmediawire.com

Oncocyte Prices $29.1 Million Equity Offering

2025-01-08prismmediawire.com

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

2025-01-06prismmediawire.com

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

2024-12-06prismmediawire.com

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

2024-12-02prismmediawire.com

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

2024-11-12seekingalpha.com

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-10 2025-08-11 2024-11-12 2024-08-08 2024-05-15 2023-11-09 2023-08-10 2023-05-15 2022-11-10 2022-08-12
acceptedDate 2025-11-10 16:15:23 2025-08-11 16:11:34 2025-03-24 16:16:17 2024-11-12 16:08:34 2024-08-08 16:27:19 2024-05-15 16:06:48 2024-04-15 21:55:32 2023-11-09 17:19:59 2023-08-10 16:50:24 2023-05-12 21:17:43 2023-04-12 16:54:07 2022-11-10 16:47:06 2022-08-11 19:08:43 2022-03-11 17:17:56 2021-03-19 17:30:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 260 000 518 000 2M 115 000 104 000 176 000 2M 429 000 463 000 297 000 958 000 1M 2M 8M 1M
costOfRevenue 121 000 168 000 1M 65 000 54 000 511 000 1M 181 000 191 000 287 000 976 000 2M 2M 8M 2M
grossProfit 139 000 350 000 740 000 50 000 50 000 -335 000 413 000 248 000 272 000 10000 -18 000 -1M -314 000 188 000 -639 000
grossProfitRatio 0.535 0.676 0.435 0.481 -1.903 0.578 0.587 0.034 -1.154 -0.152
researchAndDevelopmentExpenses 4M 3M 10M 3M 2M 2M 9M 2M 2M 2M 7M 4M 6M 14M 10M
generalAndAdministrativeExpenses 3M 3M 10M 3M 2M 3M 11M 2M 4M 3M 22M 9M 8M 22M 17M
sellingAndMarketingExpenses 1M 372 000 4M 1M 853 000 84 000 3M 713 000 81 000 695 000 1M 407 000 691 000 11M 6M
sellingGeneralAndAdministrativeExpenses 4M 4M 14M 4M 3M 4M 14M 3M 4M 4M 23M 9M 9M 34M 23M
otherExpenses 3M 3M 38M 7M 0 153 000 3M -4000 -16 000 50 000 -67 000 0 0 -37 000 27 000
operatingExpenses 11M 10M 62M 14M 6M 5M 26M 5M 6M 6M 30M 14M 14M 47M 33M
costAndExpenses 11M 10M 63M 14M 6M 6M 27M 6M 6M 7M 31M 16M 17M 55M 35M
interestIncome 0 0 0 0 0 0 0 117 000 1000 0 0 0 0 0 0
interestExpense 29 000 25 000 84 000 31 000 8000 15 000 52 000 117 000 1000 10000 83 000 14 000 21 000 209 000 252 000
depreciationAndAmortization 584 000 559 000 2M 340 000 326 000 335 000 2M 426 000 5M 50 000 5M -4M 1M 4M 394 000
ebitda -10M -9M -59M -13M -4M -5M -23M -4M -3M -6M -13M -13M -7M -48M -31M
ebitdaratio -39.388 -17.68 -114.104 -40.346 -30.972 -8.559 -7.043 -20.788 -13.152 -3.347
operatingIncome -11M -10M -61M -14M -5M -6M -25M -7M -8M -6M -18M -9M -9M -47M -30M
operatingIncomeRatio -42.492 -19 -117.522 -44.538 -32.875 -15.182 -17.914 -20.956 -9.067 -4.142
totalOtherIncomeExpensesNet 194 000 100 000 378 000 22 000 102 000 -3M 281 000 -1M -39 000 12M -615 000 -112 000 262 000 854 000 -1M
incomeBeforeTax -11M -10M -61M -13M -5M -9M -25M -6M -8M 6M -19M -9M -8M -73M -31M
incomeBeforeTaxRatio -41.746 -18.807 -117.33 -43.558 -51.869 -15.126 -17.998 20.064 -9.177 -4.015
incomeTaxExpense 0 0 0 0 0 0 0 922 000 0 3M 0 112 000 0 -9M -1M
netIncome -11M -10M -61M -13M -5M -9M -28M -6M -8M 3M -73M -9M -8M -64M -30M
netIncomeRatio -41.746 -18.807 -117.33 -43.558 -51.869 -15.126 -17.998 10.212 -9.287 -4.015
eps -0.34 -0.3 -4.66 -0.98 -0.36 -1.1 -3.75 -0.79 -20.6 0.02 -13.26 -0.08 -0.07 -14.42 -9.14
epsdiluted -0.34 -0.3 -0.98 -0.36 -1.1 -0.79 -20.6 0.02 -0.08 -0.07
weightedAverageShsOut 320 330 32M 13M 14M 13M 8M 8M 8M 404 500 119M 6M 119M 113M 4M 3M
weightedAverageShsOutDil 320 330 32M 13M 14M 13M 8M 8M 8M 404 500 119M 6M 119M 113M 4M 3M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-04-16 2023-04-12 2022-03-11 2021-03-19
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -84 000 -52 000 -83 000 -209 000 -252 000
ebit -61M -25M -19M -53M -31M
nonOperatingIncomeExcludingInterest -462 000 -333 000 532 000 -1M 1M
netIncomeFromContinuingOperations -61M -25M -19M -44M -30M
netIncomeFromDiscontinuedOperations 0 -3M -54M -20M 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 942 000 520 000 0 0
bottomLineNetIncome -61M -29M -73M -64M -30M
epsDiluted -4.66 -3.75 -13.26 -14.42 -9.14

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-10 2025-08-11 2024-11-12 2024-08-08 2024-05-15 2023-11-09 2023-08-10 2023-05-15 2022-11-10 2022-08-12
acceptedDate 2025-11-10 16:15:23 2025-08-11 16:11:34 2025-03-24 16:16:17 2024-11-12 16:08:34 2024-08-08 16:27:19 2024-05-15 16:06:48 2024-04-15 21:55:32 2023-11-09 17:19:59 2023-08-10 16:50:24 2023-05-12 21:17:43 2023-04-12 16:54:07 2022-11-10 16:47:06 2022-08-11 19:08:43 2022-03-11 17:17:56 2021-03-19 17:30:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 19M 24M 9M 3M 9M 6M 9M 14M 17M 12M 20M 32M 45M 36M 7M
shortTermInvestments 0 0 0 0 0 0 0 441 000 530 000 553 000 433 000 419 000 579 000 904 000 675 000
cashAndShortTermInvestments 19M 24M 9M 3M 9M 6M 9M 14M 18M 12M 20M 32M 45M 37M 8M
netReceivables 258 000 512 000 2M 209 000 85 000 161 000 484 000 2M 2M 2M 2M 2M 2M 1M 203 000
inventory 471 000 693 000 410 000 232 000 0 1 0 139 000 191 000 421 000 0 0 0 304 000 0
otherCurrentAssets 2M 1M 1M 989 000 627 000 796 000 782 000 672 000 1M 970 000 3M 2M 2M 3M 941 000
totalCurrentAssets 21M 27M 12M 5M 10M 7M 11M 17M 21M 16M 26M 37M 49M 39M 9M
propertyPlantEquipmentNet 2M 7M 3M 3M 6M 6M 5M 6M 8M 8M 11M 12M 12M 9M 7M
goodwill 0 0 0 0 0 0 0 0 0 0 0 19M 19M 19M 9M
intangibleAssets 15M 15M 15M 57M 57M 57M 57M 57M 57M 57M 62M 88M 89M 91M 15M
goodwillAndIntangibleAssets 15M 15M 15M 57M 57M 57M 57M 57M 57M 57M 62M 107M 108M 110M 24M
longTermInvestments 0 0 2M 0 0 2M 0 2M 2M 0 2M 0 0 2M 13M
taxAssets 0 0 0 0 0 0 0 -2M -2M 0 -2M 0 0 -2M 118 000
otherNonCurrentAssets 6M 2M 4M 6M 2M 438 000 2M 2M -6M 2M 2M 2M 2M 2M 2M
totalNonCurrentAssets 23M 24M 23M 65M 65M 64M 64M 65M 59M 67M 75M 121M 122M 120M 46M
otherAssets 0 0 0 0 0 0 0 0 8M 0 0 0 0 0 0
totalAssets 44M 51M 35M 70M 75M 71M 75M 82M 88M 83M 100M 157M 171M 160M 55M
accountPayables 1M 1M 2M 872 000 1M 908 000 953 000 1M 875 000 1M 1M 2M 2M 2M 432 000
shortTermDebt 2M 3M 1M 1M 1M 821 000 0 720 000 737 000 775 000 815 000 827 000 1M 2M 3M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 6M -737 000 0 0 0 0 0 5M
otherCurrentLiabilities 5M 2M 872 000 7M 5M 7M 4M 90 000 7M 7M 7M 10M 10M 7M 2M
totalCurrentLiabilities 8M 7M 7M 9M 7M 8M 7M 8M 8M 9M 12M 13M 14M 14M 9M
longTermDebt 2M 2M 0 3M 3M 3M 0 2M 2M 3M 0 3M 3M 0 2M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 44M 41M 38M 49M 42M 43M 40M 34M 34M 33M 51M 65M 66M 77M 7M
totalNonCurrentLiabilities 45M 43M 40M 51M 45M 46M 42M 36M 36M 35M 54M 68M 69M 80M 13M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 3M 4M 4M 4M 3M 3M 3M 3M 3M 4M 4M 4M 4M 5M
totalLiabilities 53M 49M 47M 61M 52M 54M 49M 44M 44M 45M 66M 80M 83M 94M 22M
preferredStock 0 0 0 0 0 5M 5M 5M 5M 6M 0 5M 5M 0 0
commonStock 369M 368M 338M 327M 326M 311M 310M 310M 310M 296M 295M 293M 290M 253M 157M
retainedEarnings -378M -367M -351M -317M -304M -299M -290M -272M -266M -258M -261M -216M -206M -188M -124M
accumulatedOtherComprehensiveIncomeLoss 86 000 85 000 21 000 57 000 37 000 40 000 49 000 32 000 41 000 43 000 39 000 19 000 31 000 37 000 0
othertotalStockholdersEquity 0 0 0 0 0 -5M -5M -6M -5M 0
totalStockholdersEquity -9M 1M -12M 10M 23M 17M 26M 38M 44M 38M 34M 77M 88M 65M 33M
totalEquity -9M 1M -12M 10M 23M 17M 26M 38M 44M 38M 34M 77M 88M 65M 33M
totalLiabilitiesAndStockholdersEquity 44M 51M 70M 75M 71M 82M 88M 83M 157M 171M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 44M 51M 35M 70M 75M 71M 75M 82M 88M 83M 100M 157M 171M 160M 55M
totalInvestments 0 0 2M 0 2M 2M 0 441 000 530 000 553 000 2M 419 000 0 904 000 14M
totalDebt 3M 3M 4M 4M 4M 3M 3M 3M 3M 3M 4M 4M 5M 6M 9M
netDebt -16M -21M -5M 628 000 -6M -2M -7M -11M -14M -8M -16M -28M -40M -30M 1M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-04-16 2023-04-12 2022-03-11 2021-03-19
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 2M 484 000 2M 1M 203 000
otherReceivables 0 0 0 0 0
prepaids 0 0 0 901 000 264 000
totalPayables 2M 953 000 1M 2M 432 000
otherPayables 0 0 0 0 0
accruedExpenses 2M 2M 2M 3M 4M
capitalLeaseObligationsCurrent 1M 665 000 815 000 819 000 422 000
capitalLeaseObligationsNonCurrent 2M 2M 3M 4M 4M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 0 0 -5M 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX OCX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-10 2025-08-11 2024-11-12 2024-08-08 2024-05-15 2023-11-09 2023-08-10 2023-05-15 2022-11-10 2022-08-12
acceptedDate 2025-11-10 16:15:23 2025-08-11 16:11:34 2025-03-24 16:16:17 2024-11-12 16:08:34 2024-08-08 16:27:19 2024-05-15 16:06:48 2024-04-15 21:55:32 2023-11-09 17:19:59 2023-08-10 16:50:24 2023-05-12 21:17:43 2023-04-12 16:54:07 2022-11-10 16:47:06 2022-08-11 19:08:43 2022-03-11 17:17:56 2021-03-19 17:30:01
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -11M -10M -61M -13M -5M -9M -28M -6M -8M 3M -73M -9M -8M -64M -30M
depreciationAndAmortization 584 000 559 000 2M 340 000 326 000 335 000 2M 426 000 457 000 472 000 5M 1M 1M 4M 2M
deferredIncomeTax 0 0 0 0 0 0 0 2M 24 000 0 0 0 0 -9M -1M
stockBasedCompensation 507 000 578 000 2M 354 000 202 000 464 000 7M 608 000 834 000 834 000 10M 3M 2M 7M 5M
changeInWorkingCapital 2M -478 000 -1M 160 001 -1M 1M -4M 113 000 -2M -2M -2M -539 000 82 000 -2M 399 000
accountsReceivables 254 000 3M -1M -124 000 76 000 323 000 109 000 -166 000 185 000 111 000 -575 000 -188 000 320 000 -1M -182 000
inventory 222 000 -234 000 -410 000 -232 000 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 1M -3M 967 000 649 000 -1M 854 000 -5M 126 000 -2M -3M 297 000 183 000 260 000 -1M 854 000
otherWorkingCapital 0 -3M -749 000 -132 999 -15 000 -158 000 677 000 153 000 -137 000 3M -2M -534 000 -498 000 373 000 -273 000
otherNonCashItems 4M 3M 38M 7M -797 000 3M 174 000 1M 2M -12M 14M -6M -7M 29M -2M
netCashProvidedByOperatingActivities -5M -6M -21M -6M -6M -4M -23M -2M -7M -10M -46M -11M -11M -36M -26M
investmentsInPropertyPlantAndEquipment 656 000 -349 000 -516 000 215 000 -191 000 -24 000 -281 000 -17 000 0 0 -4M -859 000 -1M -2M -1M
acquisitionsNet 0 0 0 0 0 0 0 231 000 123 000 0 0 0 0 -12M -11M
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -4M
salesMaturitiesOfInvestments 0 0 0 0 0 0 367 000 0 0 0 0 0 0 0 4M
otherInvestingActivites -2M 0 -302 000 0 -24 000 -2M 0 0 0 0
netCashUsedForInvestingActivites -1M -349 000 -87 000 -191 000 -24 000 -1M 123 000 0 -859 000 -1M
debtRepayment 0 -114 000 -86 000 0 0 -30 000 -29 000 -28 000 -572 000 -372 000
commonStockIssued -29M 0 18 000 15M 0 0 14M 0 0 33M
commonStockRepurchased 0 0 0 0 -5M 0 -1M 0 118 000 0 0 0 0 -239 000 -14 000
dividendsPaid 0 0 0 0 0 0 -118 000 0 0 0
otherFinancingActivites -120 000 0 -187 000 10M 0 -30 000 -2M 0 0 4M
netCashUsedProvidedByFinancingActivities -120 000 -114 000 -255 000 10M 0 -30 000 12M -28 000 -572 000 37M
effectOfForexChangesOnCash -105 000 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -6M -7M -796 000 -4M 4M -4M -12M -4M 6M -10M -14M -13M 24M 28M -15M
cashAtEndOfPeriod 20M 26M 10M 5M 9M 6M 11M 15M 19M 14M 23M 34M 47M 37M 9M
cashAtBeginningOfPeriod 26M 33M 11M 9M 6M 9M 23M 19M 14M 23M 37M 47M 22M 9M 24M
operatingCashFlow -5M -6M -21M -6M -6M -4M -23M -2M -7M -10M -46M -11M -11M -36M -26M
capitalExpenditure 656 000 -349 000 -516 000 215 000 -191 000 -24 000 -281 000 -17 000 0 0 -4M -859 000 -1M -2M -1M
freeCashFlow -4M -7M -21M -5M -6M -4M -24M -2M -7M -10M -50M -12M -12M -38M -27M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-04-16 2023-04-12 2022-03-11 2021-03-19
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 4000 -1M -4M -13M -7000
netCashProvidedByInvestingActivities -512 000 -932 000 -4M -14M -12M
netDebtIssuance -201 000 -117 000 -1M -2M 695 000
longTermNetDebtIssuance -201 000 -117 000 -1M -2M 1M
shortTermNetDebtIssuance 0 0 0 0 -375 000
netStockIssuance 22M 13M 38M 78M 21M
netCommonStockIssuance 28M 14M 33M 78M 21M
commonStockIssuance 28M 14M 33M 78M 21M
netPreferredStockIssuance -5M -1M 5M 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -2M -427 000 -483 000 2M 1M
netCashProvidedByFinancingActivities 20M 12M 36M 78M 23M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-10 ET (fiscal 2025 q3)
2025 q2
2025-08-11 ET (fiscal 2025 q2)
2025 q1
2025-05-12 ET (fiscal 2025 q1)
2024 q4
2025-03-24 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-08-10 ET (fiscal 2024 q2)
2024 q1
2024-05-15 ET (fiscal 2024 q1)
2023 q4
2024-04-12 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-04-03 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-11 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2025-11-10 16:15 ET
OncoCyte Corporation reported for 2025 q3
SEC form 8
2025-11-10 16:11 ET
OncoCyte Corporation published news for 2025 q3
SEC form 8
2025-11-10 16:11 ET
OncoCyte Corporation reported for 2025 q3
SEC form 10
2025-08-11 20:11 ET
OncoCyte Corporation reported for 2025 q2
SEC form 8
2025-08-11 20:10 ET
OncoCyte Corporation published news for 2025 q2
SEC form 8
2025-08-11 20:10 ET
OncoCyte Corporation reported for 2025 q2
SEC form 10
2025-05-12 20:12 ET
OncoCyte Corporation reported for 2025 q1
SEC form 10
2025-05-12 00:00 ET
OncoCyte Corporation reported for 2025 q1
SEC form 8
2025-05-12 00:00 ET
OncoCyte Corporation published news for 2025 q1
SEC form 8
2025-05-12 00:00 ET
OncoCyte Corporation reported for 2025 q1
SEC form 8
2025-04-17 21:17 ET
OncoCyte Corporation published news for 2025 q1
SEC form 8
2025-04-17 21:17 ET
OncoCyte Corporation published news for 2025 q1
SEC form 10
2025-03-24 20:16 ET
OncoCyte Corporation reported for 2024 q4
SEC form 10
2025-03-24 00:00 ET
OncoCyte Corporation reported for 2024 q4
SEC form 8
2025-03-24 00:00 ET
OncoCyte Corporation published news for 2024 q4
SEC form 8
2025-03-24 00:00 ET
OncoCyte Corporation reported for 2024 q4
SEC form 10
2024-11-12 16:08 ET
OncoCyte Corporation reported for 2024 q3
SEC form 8
2024-11-12 16:05 ET
OncoCyte Corporation published news for 2024 q3
SEC form 8
2024-11-12 16:05 ET
OncoCyte Corporation reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
OncoCyte Corporation reported for 2024 q3
SEC form 10
2024-08-08 00:00 ET
OncoCyte Corporation reported for 2024 q2
SEC form 8
2024-08-08 00:00 ET
OncoCyte Corporation published news for 2024 q2
SEC form 8
2024-08-08 00:00 ET
OncoCyte Corporation reported for 2024 q2
SEC form 10
2024-05-15 00:00 ET
OncoCyte Corporation reported for 2024 q1
SEC form 8
2024-05-15 00:00 ET
OncoCyte Corporation published news for 2024 q1
SEC form 8
2024-05-15 00:00 ET
OncoCyte Corporation reported for 2024 q1
SEC form 10
2024-04-16 00:00 ET
OncoCyte Corporation reported for 2023 q4
SEC form 10
2023-11-09 17:19 ET
OncoCyte Corporation reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
OncoCyte Corporation reported for 2023 q3
SEC form 8
2023-11-09 00:00 ET
OncoCyte Corporation reported for 2023 q3
SEC form 10
2023-08-10 16:50 ET
OncoCyte Corporation reported for 2023 q2
SEC form 6
2023-08-10 07:05 ET
OncoCyte Corporation reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
OncoCyte Corporation reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
OncoCyte Corporation reported for 2023 q2
SEC form 6
2023-07-24 17:28 ET
OncoCyte Corporation published news for 2023 q2
SEC form 6
2023-07-14 06:03 ET
OncoCyte Corporation published news for 2023 q2
SEC form 6
2023-07-10 11:20 ET
OncoCyte Corporation published news for 2023 q2
SEC form 6
2023-06-30 16:14 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-06-29 16:05 ET
OncoCyte Corporation published news for 2023 q1
SEC form 10
2023-05-15 00:00 ET
OncoCyte Corporation reported for 2023 q1
SEC form 6
2023-05-11 08:05 ET
OncoCyte Corporation reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
OncoCyte Corporation reported for 2023 q1
SEC form 6
2023-05-01 16:47 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-04-13 16:50 ET
OncoCyte Corporation published news for 2023 q1
SEC form 10
2023-04-12 16:54 ET
OncoCyte Corporation reported for 2022 q4
SEC form 10
2023-04-12 00:00 ET
OncoCyte Corporation reported for 2022 q4
SEC form 6
2023-04-06 17:25 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-04-05 09:00 ET
OncoCyte Corporation published news for 2023 q1
SEC form 8
2023-04-05 00:00 ET
OncoCyte Corporation published news for 2023 q1
SEC form 6
2023-03-31 18:02 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-03-31 17:28 ET
OncoCyte Corporation reported for 2022 q4
SEC form 8
2023-03-31 00:00 ET
OncoCyte Corporation reported for 2022 q4
SEC form 6
2023-03-02 09:05 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-23 17:00 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-17 16:08 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-13 16:07 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-02-03 16:05 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2023-01-30 16:05 ET
OncoCyte Corporation published news for 2022 q4
SEC form 6
2022-12-21 06:05 ET
OncoCyte Corporation published news for 2022 q3
SEC form 6
2022-12-05 16:05 ET
OncoCyte Corporation published news for 2022 q3
SEC form 6
2022-11-23 16:05 ET
OncoCyte Corporation published news for 2022 q3
SEC form 10
2022-11-10 16:47 ET
OncoCyte Corporation reported for 2022 q3
SEC form 6
2022-11-10 16:42 ET
OncoCyte Corporation published news for 2022 q3
SEC form 10
2022-11-10 00:00 ET
OncoCyte Corporation reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
OncoCyte Corporation reported for 2022 q3
SEC form 6
2022-11-09 16:06 ET
OncoCyte Corporation published news for 2022 q3
SEC form 6
2022-09-26 16:11 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-08-15 16:16 ET
OncoCyte Corporation published news for 2022 q2
SEC form 10
2022-08-12 00:00 ET
OncoCyte Corporation reported for 2022 q2
SEC form 10
2022-08-11 19:08 ET
OncoCyte Corporation reported for 2022 q2
SEC form 6
2022-08-10 16:10 ET
OncoCyte Corporation published news for 2022 q2
SEC form 8
2022-08-10 00:00 ET
OncoCyte Corporation reported for 2022 q2
SEC form 6
2022-08-03 16:05 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-08-01 08:05 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-07-21 16:05 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-07-15 08:00 ET
OncoCyte Corporation published news for 2022 q2
SEC form 6
2022-06-30 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-06-08 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-05-26 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 10
2022-05-12 16:27 ET
OncoCyte Corporation reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
OncoCyte Corporation reported for 2022 q1
SEC form 6
2022-05-11 16:11 ET
OncoCyte Corporation published news for 2022 q1
SEC form 8
2022-05-11 00:00 ET
OncoCyte Corporation reported for 2022 q1
SEC form 6
2022-05-02 16:05 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-04-19 16:01 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-04-13 17:09 ET
OncoCyte Corporation published news for 2022 q1
SEC form 6
2022-03-14 06:05 ET
OncoCyte Corporation published news for 2021 q4
SEC form 10
2022-03-11 17:17 ET
OncoCyte Corporation published news for 2021 q4
SEC form 10
2022-03-11 00:00 ET
OncoCyte Corporation published news for 2021 q4
SEC form 6
2022-03-10 16:10 ET
OncoCyte Corporation published news for 2021 q4
SEC form 8
2022-03-10 00:00 ET
OncoCyte Corporation published news for 2021 q4
SEC form 6
2022-01-18 16:19 ET
OncoCyte Corporation published news for 2021 q4
SEC form 6
2021-12-14 16:30 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-12-08 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 10
2021-11-09 17:21 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-11-09 16:37 ET
OncoCyte Corporation published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
OncoCyte Corporation published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-11-04 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-10-27 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-10-07 08:05 ET
OncoCyte Corporation published news for 2021 q3
SEC form 6
2021-09-20 11:40 ET
OncoCyte Corporation published news for 2021 q2
SEC form 10
2021-08-11 15:24 ET
OncoCyte Corporation published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
OncoCyte Corporation published news for 2021 q2
SEC form 6
2021-08-10 17:12 ET
OncoCyte Corporation published news for 2021 q2
SEC form 6
2021-07-20 16:47 ET
OncoCyte Corporation published news for 2021 q2
SEC form 6
2021-06-28 17:17 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-06-24 08:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-06-11 19:41 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-06-01 16:25 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-21 16:05 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-21 08:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-17 17:19 ET
OncoCyte Corporation published news for 2021 q1
SEC form 10
2021-05-17 16:06 ET
OncoCyte Corporation published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-05-10 08:00 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-04-30 08:30 ET
OncoCyte Corporation published news for 2021 q1
SEC form 6
2021-04-19 13:44 ET
OncoCyte Corporation published news for 2021 q1
SEC form 10
2021-03-19 17:30 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-03-16 16:36 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-03-01 16:30 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-25 08:00 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-22 08:00 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-05 17:15 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-04 17:15 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-03 09:07 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-02-02 16:36 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2021-01-21 08:24 ET
OncoCyte Corporation published news for 2020 q4
SEC form 6
2020-12-16 06:00 ET
OncoCyte Corporation published news for 2020 q3
SEC form 6
2020-11-30 09:00 ET
OncoCyte Corporation published news for 2020 q3
SEC form 10
2020-11-12 16:50 ET
OncoCyte Corporation published news for 2020 q3
SEC form 6
2020-11-12 16:30 ET
OncoCyte Corporation published news for 2020 q3